Mr. Ashish Malik reports

BEE VECTORING TECHNOLOGIES ANNOUNCES RUTGERS UNIVERSITY'S YEAR 2 POSITIVE TRIAL RESULTS: REDUCED FUNGAL DISEASE AND BETTER BEE HEALTH

Bee Vectoring Technologies International Inc. (BVT) is cheering Rutgers University's completion of year 2 research trials on the efficacy of BVT's proprietary Vectorite with CR-7 (Clonostachys rosea CR-7), applied with bee vectoring technology to New Jersey blueberry crops during the 2022 growing season. Furthermore, the bee colony health was also assessed in year 2.

Both year 1 and year 2 trials were conducted by Rutgers University's specialty crop research and extension centre and PE Marucci Blueberry Cranberry Research & Extension Center, a leading, grower-trusted research centre in the United States Northeast. The 2022 trial further assessed the efficacy of the BVT system in controlling common fungal diseases and increasing yield of healthy berries after harvest, both critical measures of the time span picked berries remain fresh.

"Growers and researchers alike are required to see multiyear data to confirm efficacy and, once again, BVT produced fantastic results," said Dr. Mason Newark, field technical manager at BVT. "Rutgers's year 2 trial results remain consistent with year 1, showing that the BVT system is equivalent for disease control, and sometimes better than a standard spray program using chemical fungicides that can be harmful to plants, soil, water, pollinators and workers in the fields."

Data was collected from established blueberry fields where BVT's biological fungicide CR-7 was bee vectored, then compared with collected data from the same field beyond the vectored range where a grower standard program was applied. In the grower standard locations, some growers sprayed six applications of chemical fungicides while other sites received up to 12 applications of chemical fungicides.

When comparing results of the BVT honeybee system with CR-7 used alone to the grower standard process, year 2 results demonstrated:

• BVT's honeybee system and biofungicide kept 66 per cent of harvested berries healthy and marketable after seven days of incubation, which is comparable to the grower standard's value of 64 per cent under the same conditions.
• The BVT system alone was statistically equivalent to the grower standard in controlling Anthracnose disease infections postharvest.
• The BVT system alone outperformed the grower standard spray program in controlling Alternaria disease infections postharvest.

Marketable yield data is currently being analyzed by the Rutgers research team and will be available over the next one to two months.

"These results continue to indicate that the BVT technology concretely helps to consistently reduce fungal disease occurrence," said Chelsea Abegg, technician and PhD candidate at Rutgers University's specialty crop research and extension centre.

"Growers like to see multiple years of field data, especially third party research, prior to deploying a new system and these compelling results will assist in convincing prospective growers to join the program," said Ian Collinson, sales manager at BVT.

In the 2022 trial, Rutgers also tracked and evaluated bee health. Trial results show that commercial honeybees being used with the BVT system were healthier than those in fields with a traditional fungicide spray program (the control group), including:

• Better weight increases: Hives used with the BVT system had a significant increase in hive weight.
• Less brood reduction: Hives used with the BVT system experienced significantly lower reductions in brood.
• Better colony health indices: Hives used with the BVT system showed significantly better health (Health indices is a set of parameters beyond traditional weight and brood measurements).

These trial results are particularly notable because honeybees are pivotal to crop production, food security and the economy. Over the years, beekeepers and growers have experienced a significant increase in colony losses. Therefore, it is a significant benefit when hives are healthier after crop pollination.

"Certain commonly used fungicides cause neurological problems for bees," said Ms. Abegg. "These trial results are promising in that they demonstrate that the BVT system has less impact on bees than traditional spray programs. The hives were heavier at the end of season, with more brood coverage and had a higher colony health index score as compared to hives without the BVT system installed."

"The results of the bee hive and health study by a skilled third party at a leading research university once again has validated BVT's strong sustainability position in the critical field of pollination and bee health. New, proven approaches and natural plant protection products are an important part of preventing further colony loss -- we need to do everything we can for these vital pollination partners," continued Dr. Newark.

About Bee Vectoring Technologies International Inc.

BVT, an agriculture technology company, is a market disrupter with a significant global market opportunity in the $240-billion crop protection and fertilizer market. BVT has pioneered a natural precision agriculture system that replaces chemical pesticides and wasteful plant protection product spray applications by delivering biological pesticide alternatives to crops using commercially grown bees. BVT's award-winning technology, precision vectoring, is completely harmless to bees and allows minute amounts of naturally derived pesticides (called biologicals) to be delivered directly to blooms, providing improved crop protection and yield results than traditional chemical pesticides -- and improving the health of the soil, the microbiome and the environment. Currently, BVT has over 65 granted patents, over 35 patents pending in all major agricultural countries worldwide and has U.S. EPA (Environmental Protection Agency)registration of its Vectorite with CR-7 (EPA Registration No. 90641-2) for sale as a registered biological fungicide for use on the labelled crops.

We seek Safe Harbor.